Compare Adaptive Biotechnologies Corp (ADPT) vs Banco Santander SA (SAN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Adaptive Biotechnologies Corp vs Banco Santander SA — how do they compare? Adaptive Biotechnologies Corp trades at $25.5 (market cap $4.04B), while Banco Santander SA trades at $14.88 (market cap $211.63B). The key difference: Banco Santander SA is far larger — about 52.4× Adaptive Biotechnologies Corp's market cap, and Banco Santander SA pays a 1.89% dividend while Adaptive Biotechnologies Corp pays none. Which is the better fit depends on your goals.
| ADPT | SAN | |
|---|---|---|
Market Cap | $4.04B | $211.63B |
Sector | Health | Financials |
52-Week High | $25.45 | $14.71 |
52-Week Low | $12.30 | $9.37 |
Enterprise Value | $4.10B | — |
Dividend Yield | — | 1.89% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
Banco Santander (SAN) trades at $14.69, showing minimal daily movement with a slight decline of 0.07%. The stock maintains a bullish technical signal supported by moving averages, while oscillators indicate neutral momentum. Fundamentally, the company reported strong profitability with a 26.25% net income margin and record quarterly profits in Q2 2026. Recent developments include Federal Reserve approval for the $12 billion Webster Bank acquisition, positioning Santander for strategic expansion.
The outlook remains positive with analyst consensus favoring Buy ratings (64%) and the company achieving Spain's most valuable listed company status. Key risks include volatile cash flow trends with negative operating cash flow in 2024-2025 and restructuring charges from recent acquisitions. Revenue growth is projected to reach $61.9B in 2026, supporting continued investor confidence despite near-term earnings volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Adaptive Biotechnologies Corp
Adaptive Biotechnologies Corp is a commercial-stage company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease in patients with select blood cancers.
Read more on ADPT →About Banco Santander SA
Santander's focus is on retail and commercial banking. Latin America is geographically the largest operation, with Brazil by far the largest. Its continental European business is still mainly Iberian. Santander's U.K. presence is the result of the acquisition of building society Abbey. In the U.S., Santander operates a vehicle finance business and a regional bank focused on the Northeastern states.
Read more on SAN →
